Literature DB >> 2594450

Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside.

S V Sotiropoulos1, M A Jackson, G M Woods, R A Hicks, J Cullen, A I Freeman.   

Abstract

During a 2-year period after the introduction of an intensive chemotherapeutic protocol, alpha-hemolytic streptococci accounted for 75% of all episodes of sepsis among children with acute nonlymphocytic leukemia at our institution. Only one case had occurred in the previous 8 years. Fourteen of 15 episodes of streptococcal sepsis occurred after therapy with either continuous or large dosage intermittent cytosine arabinoside. Eleven episodes occurred at two specific treatment points. Septic episodes were complicated by shock (2 of 15), encephalopathy (2 of 15), pneumonia (3 of 15) and death (1 of 15). Oral mucosal lesions may provide a portal of entry for alpha-hemolytic streptococci. These data suggest that children receiving continuous or large dosage intermittent cytosine arabinoside for treatment of acute nonlymphocytic leukemia may be at increased risk for alpha-hemolytic streptococcal sepsis. Empiric antimicrobial therapy in these children when febrile and neutropenic should include antibiotics effective against alpha-hemolytic streptococci.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2594450     DOI: 10.1097/00006454-198911000-00005

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

1.  In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients.

Authors:  F Alcaide; J Carratala; J Liñares; F Gudiol; R Martin
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia.

Authors:  W Kern; E Kurrle
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

3.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

4.  Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin.

Authors:  P H McWhinney; S Patel; R A Whiley; J M Hardie; S H Gillespie; C C Kibbler
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

5.  Prevention of infection in children with acute leukaemia. No major difference between total and selective bowel decontamination.

Authors:  N Muis; W A Kamps; J Dankert
Journal:  Support Care Cancer       Date:  1996-05       Impact factor: 3.603

6.  Association and risk factors of healthcare-associated infection and burden of illness among chemotherapy-induced ulcerative mucositis patients.

Authors:  P S Satheeshkumar; M P Mohan
Journal:  Clin Oral Investig       Date:  2021-08-06       Impact factor: 3.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.